logo
NasdaqGS:INSM logo

Insmed Community

NasdaqGS:INSM Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

INSM logo
Insmed
AN
AnalystConsensusTarget
Consensus Narrative from 17 Analysts

Brensocatib's 2025 Launch Will Transform Bronchiectasis Care

Key Takeaways Anticipated U.S. and international launches of brensocatib are key catalysts for significant revenue growth and new market penetration. Strategic investment in market access and R&D aims to sustain long-term profitability and support efficient product launches.
View narrative
US$97.12
FV
32.4% undervalued intrinsic discount
72.03%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
9 days ago author updated this narrative